Celgene Corporation (CELG) is Exane Asset Management’s 10th Largest Position

Exane Asset Management lowered its position in Celgene Corporation (NASDAQ:CELG) by 5.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 101,756 shares of the biopharmaceutical company’s stock after selling 5,436 shares during the period. Celgene Corporation accounts for about 4.1% of Exane Asset Management’s portfolio, making the stock its 10th largest position. Exane Asset Management’s holdings in Celgene Corporation were worth $13,215,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. First Quadrant L P CA increased its position in shares of Celgene Corporation by 164.4% in the second quarter. First Quadrant L P CA now owns 269,210 shares of the biopharmaceutical company’s stock valued at $34,962,000 after buying an additional 167,394 shares in the last quarter. Aperio Group LLC increased its position in shares of Celgene Corporation by 8.8% in the second quarter. Aperio Group LLC now owns 434,966 shares of the biopharmaceutical company’s stock valued at $56,489,000 after buying an additional 35,145 shares in the last quarter. Tarbox Family Office Inc. increased its position in shares of Celgene Corporation by 315.5% in the second quarter. Tarbox Family Office Inc. now owns 1,317 shares of the biopharmaceutical company’s stock valued at $171,000 after buying an additional 1,000 shares in the last quarter. Glenview State Bank Trust DEPT. increased its position in shares of Celgene Corporation by 2.8% in the second quarter. Glenview State Bank Trust DEPT. now owns 14,450 shares of the biopharmaceutical company’s stock valued at $1,877,000 after buying an additional 400 shares in the last quarter. Finally, Sippican Capital Advisors increased its position in shares of Celgene Corporation by 28.0% in the second quarter. Sippican Capital Advisors now owns 5,777 shares of the biopharmaceutical company’s stock valued at $750,000 after buying an additional 1,264 shares in the last quarter. 78.34% of the stock is owned by institutional investors.

Celgene Corporation (NASDAQ:CELG) opened at 127.65 on Friday. Celgene Corporation has a 52 week low of $96.93 and a 52 week high of $139.00. The company has a market cap of $99.87 billion, a price-to-earnings ratio of 39.53 and a beta of 1.89. The firm has a 50-day moving average of $133.74 and a 200-day moving average of $124.92.

Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The company had revenue of $3.27 billion during the quarter, compared to analyst estimates of $3.23 billion. During the same quarter last year, the firm posted $1.44 EPS. The firm’s revenue for the quarter was up 18.7% on a year-over-year basis. Equities analysts forecast that Celgene Corporation will post $7.32 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Celgene Corporation (CELG) is Exane Asset Management’s 10th Largest Position” was published by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.com-unik.info/2017/08/19/celgene-corporation-celg-shares-sold-by-exane-asset-management-2-updated-updated.html.

Several equities analysts recently issued reports on the stock. Vetr raised shares of Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 price target for the company in a report on Wednesday. Oppenheimer Holdings, Inc. reissued an “outperform” rating and set a $175.00 price target on shares of Celgene Corporation in a report on Wednesday, August 9th. Cann reissued a “buy” rating and set a $175.00 price target on shares of Celgene Corporation in a report on Tuesday, August 1st. Jefferies Group LLC reissued a “buy” rating and set a $160.00 price target on shares of Celgene Corporation in a report on Monday, July 31st. Finally, Argus upgraded shares of Celgene Corporation from a “hold” rating to a “buy” rating and raised their price objective for the company from $96.93 to $160.00 in a research report on Monday, July 31st. One research analyst has rated the stock with a sell rating, six have issued a hold rating, twenty-two have issued a buy rating and one has given a strong buy rating to the company’s stock. Celgene Corporation has an average rating of “Buy” and a consensus price target of $147.00.

In related news, insider Rupert Vessey sold 4,785 shares of Celgene Corporation stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $120.18, for a total value of $575,061.30. Following the completion of the sale, the insider now owns 4,004 shares of the company’s stock, valued at approximately $481,200.72. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Michael D. Casey sold 9,250 shares of Celgene Corporation stock in a transaction dated Monday, June 19th. The stock was sold at an average price of $125.59, for a total value of $1,161,707.50. The disclosure for this sale can be found here. In the last three months, insiders sold 253,761 shares of company stock valued at $33,792,445. 0.95% of the stock is currently owned by insiders.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

What are top analysts saying about Celgene Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celgene Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit